血液透析患者接种BNT162b2疫苗后的早期体液免疫应答
这项前瞻性单中心研究纳入22例透析患者和46例健康对照,比较接种mRNA疫苗BNT162b2后抗S1 IgG和中和抗体的产生情况。首剂后仅18%透析患者产生阳性抗S1 IgG,而健康对照为93%;第二剂后82%透析患者产生中和抗体,但水平低于健康对照。
要点
- 透析患者首剂BNT162b2后抗体应答率显著低于健康对照。
- 第二剂后多数透析患者产生中和抗体,但滴度仍低于健康对照。
- 透析患者完成两剂疫苗接种对建立体液免疫至关重要。
核心结论
- 长期血液透析患者对BNT162b2疫苗第一剂和第二剂的抗体应答均降低。
- 第二剂后82%透析患者产生中和抗体,但水平低于健康对照。
研究设计与样本
- 检测接种第一剂后17-22天和第二剂后18-22天的抗S1 IgG、中和抗体及针对不同SARS-CoV-2片段的抗体。
主要发现
- 第一剂后,透析患者4/22(18%)抗S1 IgG阳性,健康对照43/46(93%);中位抗S1 IgG指数分别为0.2(IQR 0.1-0.7)和9(IQR 4-16)。
- 第一剂后,透析患者4/22(18%)中和抗体超过中和阈值,健康对照43/46(93%);中位抑制百分比分别为11(IQR 3-24)和65(IQR 49-75)。
- 第二剂后,透析患者14/17(82%)产生超过病毒中和阈值的中和抗体及针对Spike蛋白受体结合S1结构域的抗体,健康对照46/46(100%)。
- 第二剂后中位抑制百分比:透析患者51(IQR 32-86),健康对照98(IQR 97-98)。
关键数值与推荐
- 抗S1 IgG检测阈值指数大于1。
- 中和抗体病毒中和阈值≥30%。
临床怎么用
- 透析患者应完成两剂BNT162b2疫苗接种以增强体液免疫应答。
- 透析患者接种后抗体水平仍可能低于健康人群,需关注免疫保护不足的风险。
局限性
- 单中心小样本研究(透析患者22例,健康对照46例)。
- 仅评估早期体液免疫,未报告细胞免疫或长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients receiving hemodialysis are at high risk for both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe coronavirus disease 2019. A lifesaving vaccine is available, but sensitivity to vaccines is generally lower in patients on dialysis. Little is yet known about antibody responses after coronavirus disease 2019 (COVID-19) vaccination in this vulnerable group. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: In this prospective single-center study, we included 22 patients on dialysis and 46 healthy controls from Heidelberg University Hospital between December 2020 and February 2021. We measured anti-S1 IgG with a threshold index for detection greater than one, neutralizing antibodies with a threshold for viral neutralization of ≥30%, and antibodies against different SARS-CoV2 fragments 17-22 days after the first dose and 18-22 days after the second dose of the mRNA vaccine BNT162b2. RESULTS: After the first vaccine dose, four of 22 (18%) patients on dialysis compared with 43 of 46 (93%) healthy controls developed positive anti-S1 IgG, with a median anti-S1 IgG index of 0.2 (interquartile range, 0.1-0.7) compared with nine (interquartile range, 4-16), respectively. SARS-CoV2 neutralizing antibodies exceeded the threshold for neutralization in four of 22 (18%) patients on dialysis compared with 43 of 46 (93%) healthy controls, with a median percent inhibition of 11 (interquartile range, 3-24) compared with 65 (interquartile range, 49-75), respectively. After the second dose, 14 of 17 (82%) patients on dialysis developed neutralizing antibodies exceeding the threshold for viral neutralization and antibodies against the receptor binding S1 domain of the spike protein, compared with 46 of 46 (100%) healthy controls, respectively. The median percent inhibition was 51 (interquartile range, 32-86) compared with 98 (interquartile range, 97-98) in healthy controls. CONCLUSIONS: Patients receiving long-term hemodialysis show a reduced antibody response to the first and second doses of the mRNA vaccine BNT162b2. The majority (82%) develop neutralizing antibodies after the second dose but at lower levels than healthy controls.
引用
- Speer C, Göth D, Benning L, et al. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin J Am Soc Nephrol. 2021. PMID: 34031181. doi:10.2215/CJN.03700321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。